Hindustan Syringes & Medical Devices (HMD) one of the largest manufacturers of Disposable Syringes in the World and the largest for Auto Disable syringes has today launched most revolutionary and pioneering, India’s First “Made in India” Dispovan Insulin Pen Needle” to provide better comfort for people with diabetes at the 4th Medical Expo Indore 2018. The Dispovan Insulin pen needle is a precision engineered, yet affordable sterile single use pen needle, which can be universally fitted on all international brands of Insulin Pens. With features like, ergonomic shape for improved skin contact and grip, extra thin wall, multi-bevel, tapered point, Dispovan Insulin pen needle is designed and manufactured by HMD with intent to offer a much less painful injection experience for diabetic patients.
Founded in 1957, HMD (makers of DISPOVAN) is India’s leading medical device manufacturer with offices in USA and UK and has a annual turnover of approximately US$ 100 million. HMD is a trend setter and has pioneered innovative medical disposables to compete successfully with entrenched multibillion dollar MNC’s and became market leader of I.V.Cannulas, Syringes & Needles in India. HMD has seven highly automated plants employing over 3500 people and has a nationwide deeply entrenched customer base of over 5000 dealers. HMD’s primary international markets are USA, Europe and Middle East. All its ICMED certified products are manufactured as per ISO 9001, ISO 13485, and the European CE & US FDA standards. Besides being Jt. Managing Director of HMD, Mr.Rajiv Nath is also Forum Coordinator of Association of Indian Medical Device Industry (AIMED), and a strong advocate for Make in India for Medical Devices
According to Mr. Rajiv Nath, Jt. Managing Director of Hindustan Syringes & Medical Devices (HMD), “We are particularly excited about the prospects of our latest offering ” Dispovan Insulin Pen Needle” manufactured in our state of the art manufacturing facilities, which will end India’s import dependency and the monopoly of BD. Patients will now be able to access an affordable quality product, which they need not reuse because it is expensive. We have received excellent feedback and clinical acceptance from the end users of a comfortable injection and glad that our investments in high end technology are giving us a competitive edge.”
“With the launch of ‘Dispovan Insulin Pen Needle’ we will contribute towards our ongoing commitment of making healthcare affordable for common people in India” said Mr. Pardeep Sareen, Chief General Manager-Marketing of HMD .
“Why reuse a pen needle”, he quipped “when Dispovan makes it affordable for single use? Reuse of a Insulin pen needle could increase the following :
- Bacterial growth on the needle – Risk of injection
- Experiencing pain when injecting
- Risk of lipohypertrophy (lumpy skin) occurring
- Risk of the very fine tip of the needle breaking off
The above stated risks will grow with each re-use”, he adviced.
Dispovan Insulin Pen Needle is manufactured at HMD’s Faridabad-Ballabgarh plant. The new plant is spread on an area of 5.5 acres and will have the capacity to initially produce over 100 million units per annum of ‘Dispovan Insulin Pen Needle’ to meet the rising export and domestic demand for its new technology. Every Needle point is checked online by a Digital Vision Camera System for a defective, blunt needle point and such needles, which can be potentially painful are rejected automatically on line, he explained. The proprietary dry silicon coating used by us makes the needle surface slippery to ensure comfortable injection.
Dispovan Insulin Pen Needle has needle gauge option of 31G & 32G with needle length of 5mm & 4mm respectively and comes in purple and green colour shade to enable visual recognition of needle size.
The pricing of the Becton, Dickinson and Company (BD) pen needle is Rs.14 MRP whereas HMD has initially kept the MRP of its’ Dispovan pen needle for Rs.12. Dispovan pen needle is economical to patient by at least 15 %, as compared to imported pen needles. Unlike prices of imports that are volatile and linked to ever changing exchange rates and steady devaluation of Indian rupee that makes imports expensive, the made in India product has relatively stable pricing.
About Diabetes in India : Diabetes is one of the most prevalent diseases in the world. It is a medical condition that is caused due to insufficient production and secretion of insulin from the pancreas in case of Type-I diabetes and improper use of Insulin by the body in case of Type-2 Diabetes. Under normal body circumstances, blood glucose levels are tightly controlled by insulin, a hormone produced by the pancreas. Insulin lowers the blood glucose level. When the blood glucose elevates (for example, after eating food), insulin is released from the pancreas to normalise the glucose level. In patients with Diabetes, the absence or insufficient production of insulin causes hyperglycemia.
Diabetes is a chronic medical condition, that is, it can be curbed at the initial level by introducing lifestyle changes and controlled after its incidence through medicines in early stages and administration of external insulin in advanced stages.
It has been projected that worldwide approximately 300 million people would be afflicted with it by 2025.
- In India, about 50.9 million people suffer from Diabetes, and this figure is likely to go upto 80 million by 2025, making it the ‘Diabetes Capital’ of the world.
- Delhi alone has an estimated 29.8 lakh people suffering from this disease (Indo-US collaborative study).